Understanding treatment strategies and preferences in nonmetastatic castration-resistant prostate cancer from the Japanese physician perspective
K Suzuki, V Grillo, Y Chen, S Singh… - JCO global …, 2021 - ascopubs.org
PURPOSE Sixteen percent (16%) of patients with castration-resistant prostate cancer
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …
Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences
A Wind, ED Hartman, R Van Eekeren, R Wijn… - BMC cancer, 2021 - Springer
Background Taking patient centeredness into account is important in healthcare. The
European Cancer Consumer Quality Index (ECCQI) is a validated tool for international …
European Cancer Consumer Quality Index (ECCQI) is a validated tool for international …
[PDF][PDF] Validating a generic cancer consumer quality index in eight European Countries, patient reported experiences
A Wind - 2021 - helda.helsinki.fi
Background: Taking patient centeredness into account is important in healthcare. The
European Cancer Consumer Ouality Index (ECCO) is a validated tool for international …
European Cancer Consumer Ouality Index (ECCO) is a validated tool for international …
[PDF][PDF] SHeS UNIVERSITY OF HELSINKI
A Wind - 2021 - helda.helsinki.fi
Background: Taking patient centeredness into account is important in healthcare. The
European Cancer Consumer Ouality Index (ECCO) is a validated tool for international …
European Cancer Consumer Ouality Index (ECCO) is a validated tool for international …